Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an update.
CSL Limited has announced the issuance of 3,550 unquoted securities under an employee incentive scheme. These securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, which reflects CSL’s strategy to incentivize its workforce while maintaining a controlled equity structure.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, primarily focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies and influenza vaccines, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 990,597
Technical Sentiment Signal: Sell
Current Market Cap: A$104.2B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.